2,2-bis(ethoxymethyl)-1,3-dimethoxypropane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-bis(ethoxymethyl)-1,3-dimethoxypropane
• 英文别名: 1-Ethoxy-2-(ethoxymethyl)-3-methoxy-2-(methoxymethyl)propane；1-ethoxy-2-(ethoxymethyl)-3-methoxy-2-(methoxymethyl)propane
• 化学式: C₁₁H₂₄O₄
• 分子量: 220.309
• InChiKey: DQBKJFILECLVSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• US20140275145A1
  申请人：——

  公开号：US20140275145A1

  公开（公告）日：2014-09-18
• PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER
  申请人：HERON THERAPEUTICS, INC.

  公开号：US20150320866A1

  公开（公告）日：2015-11-12

  The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5HT3) receptor antagonist and a neurokinin-1 (NK1) receptor antagonist to a subject in need thereof. Formulations described herein are suitable for subcutaneous administration. Also described are methods of treatment of various disorders, including chemotherapy-induced nausea and vomiting (CINV). The disclosed compositions and methods provide for less frequent dosing of the therapeutic agents, thereby increasing subject comfort and compliance.
• METHOD OF TREATING PATIENTS NON-RESPONSIVE TO PALONOSETRON
  申请人：HERON THERAPEUTICS, INC.

  公开号：US20150359897A1

  公开（公告）日：2015-12-17

  A method for treating chemotherapy-induced nausea and vomiting in individuals undergoing chemotherapy and previously treated with, and whom failed to respond to, a 5-HT3 antagonist other than granisetron is described. Individuals who fail to respond to, for example, palonosetron, as evidenced by an inadequate prevention or attenuation of acute or delayed chemotherapy-induced nausea and vomiting, are treated with a semi-solid drug delivery vehicle that provides a sustained release of granisetron.
• COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
  申请人：Heron Therapeutics, Inc.

  公开号：US20170182168A1

  公开（公告）日：2017-06-29

  Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
• US9592227B2
  申请人：——

  公开号：US9592227B2

  公开（公告）日：2017-03-14